Nicholas McGrane - Evolent Health Executive Vice President of Corporate Performance
| EVH Stock | USD 27.41 0.14 0.51% |
President
Mr. Nicholas P. McGrane is Executive Vice President of Corporationrationrate Performance of the Company. He is no longer Chief Financial Officer of the Company, effective July 1, 2019. He has served as our Chief Financial Officer since October 2014. Prior to joining Evolent, Mr. McGrane was Managing Director with Riverside Management Group from July 2013 to October 2014. Prior to joining Riverside Management Group, Mr. McGrane was an independent consultant for clients including Evolent Health LLC. He served as Interim Chief Executive Officer and Interim President of Sbarro Inc. from July 2010 to February 2012. Sbarro Inc. was a portfolio company of MidOcean Partners, where Mr. McGrane held various roles, including Managing Director, from 1997 to 2012 since 2019.
| Age | 49 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 1812 N. Moore Street, Arlington, VA, United States, 22209 |
| Phone | 571 389 6000 |
| Web | https://www.evolent.com |
Evolent Health Management Efficiency
The current Return On Tangible Assets is estimated to decrease to -0.15. The current Return On Capital Employed is estimated to decrease to -0.04. As of now, Evolent Health's Other Assets are increasing as compared to previous years. The Evolent Health's current Intangible Assets is estimated to increase to about 789.6 M, while Other Current Assets are projected to decrease to under 28.8 M. Evolent Health's management efficiency ratios could be used to measure how well Evolent Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | PRESIDENT Age | ||
| Heather Getz | Heartbeam | 43 | |
| Robert Eno | Heartbeam | N/A | |
| Kevin Karas | National Research Corp | 60 | |
| Steven Jackson | National Research Corp | 42 | |
| George Hrenko | Heartbeam | 53 | |
| Jenifer Goh | EUDA Health Holdings | 34 | |
| Mohammad Noer | Mitesco | N/A | |
| Fred Broadway | Heartbeam | 48 | |
| Sugi Handoko | Mitesco | N/A | |
| Andreas Tjahjadi | Mitesco | 68 | |
Management Performance
| Return On Equity | -0.11 | ||||
| Return On Asset | 0.0086 |
Evolent Health Leadership Team
Elected by the shareholders, the Evolent Health's board of directors comprises two types of representatives: Evolent Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evolent. The board's role is to monitor Evolent Health's management team and ensure that shareholders' interests are well served. Evolent Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evolent Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan JD, General Officer | ||
| Lydia Stone, Chief Accounting Officer, Corporate Controller | ||
| Matthew Hobart, Independent Director | ||
| Thomas Peterson, Chief Operating Officer | ||
| Robert Cruz, Chief Officer | ||
| Gary Piefer, Chief Medical Officer | ||
| Dan McCarthy, CEO President | ||
| John MD, Chief Officer | ||
| Nicholas McGrane, Executive Vice President of Corporate Performance | ||
| Bridget Duffy, Independent Director | ||
| Tunde Sotunde, Independent Director | ||
| Steven Wigginton, Chief Devel. Officer | ||
| MAAA FSA, Chief Officer | ||
| Emily Rafferty, Chief Officer | ||
| Norman Payson, Director | ||
| Bruce Felt, Independent Director | ||
| John Johnson, Chief Financial Officer | ||
| Kenneth Samet, Independent Director | ||
| M Duffy, Independent Director | ||
| Craig Barbarosh, Independent Director | ||
| Michael Kirshbaum, Director | ||
| Steve Tutewohl, Chief Operating Officer | ||
| Cheryl Scott, Lead Independent Director | ||
| Charles Pomeroy, Chief Technology Officer | ||
| Seth Blackley, Chief Executive Officer, Co-Founder, Director | ||
| Frank Williams, Co-Founder, CEO, Director and Chairman of Nominating and Governance Committee | ||
| Dave Thornton, Chief Talent Officer | ||
| Jonathan Weinberg, General Counsel | ||
| David Farner, Director | ||
| Aammaad Shams, Interim Principal Accounting Officer and Corporate Controller | ||
| Jessica Somers, Sr Devel | ||
| Robert Musslewhite, Director | ||
| Seth Frank, Vice Relations | ||
| Peter Grua, Independent Director | ||
| Diane Holder, Director | ||
| Michael DAmato, Independent Director | ||
| Kali Beyah, Chief Officer | ||
| Jessica White, Chief Officer | ||
| Kim Keck, Independent Director |
Evolent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evolent Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | ||||
| Return On Asset | 0.0086 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 3.74 B | ||||
| Shares Outstanding | 116.2 M | ||||
| Shares Owned By Insiders | 3.97 % | ||||
| Shares Owned By Institutions | 96.03 % | ||||
| Number Of Shares Shorted | 11.38 M | ||||
| Price To Earning | (13.88) X |
Pair Trading with Evolent Health
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evolent Health position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evolent Health will appreciate offsetting losses from the drop in the long position's value.Moving against Evolent Stock
| 0.78 | DXR | Daxor | PairCorr |
The ability to find closely correlated positions to Evolent Health could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evolent Health when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evolent Health - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evolent Health to buy it.
The correlation of Evolent Health is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evolent Health moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evolent Health moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evolent Health can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolent Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Evolent Stock analysis
When running Evolent Health's price analysis, check to measure Evolent Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolent Health is operating at the current time. Most of Evolent Health's value examination focuses on studying past and present price action to predict the probability of Evolent Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolent Health's price. Additionally, you may evaluate how the addition of Evolent Health to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Evolent Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolent Health. If investors know Evolent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 17.653 | Quarterly Revenue Growth 0.454 | Return On Assets 0.0086 | Return On Equity (0.11) |
The market value of Evolent Health is measured differently than its book value, which is the value of Evolent that is recorded on the company's balance sheet. Investors also form their own opinion of Evolent Health's value that differs from its market value or its book value, called intrinsic value, which is Evolent Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolent Health's market value can be influenced by many factors that don't directly affect Evolent Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolent Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolent Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolent Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.